|
|
|
| Effect of three types of glucocorticoid administration on lung function and inflammatory status of acute exacerbation of chronic obscructive pulmonary disease |
| XIAO Wen-xiang LI Jing LIU Hong-mei |
| Department of Pharmacy, CITIC Huizhou Hospital Co., Ltd. CITIC Huizhou Hospital, Guangdong Province, Huizhou 516001, China |
|
|
|
|
Abstract Objective To investigate the effects of three kinds of Glucocorticoids on pulmonary function and inflammatory status of acute exacerbation of chronic obscructive pulmonary disease (AECOPD). Methods A total of 60 patients with AECOPD admitted to our hospital from September 2018 to October 2019 were selected as the research subjects,according to the random number table method, they were divided into group A (oral Prednisone), group B (intravenous Methylprednisolone), and group C (nebulized inhaled Budesonide), each had 20 cases. All three groups of patients received conventional treatments such as asthma, phlegm and cough relief, oxygen inhalation, nutritional support, and correction of electrolyte balance. Pulmonary function [forced expiratory volume in 1 second (FEV1), forced vital capacity(FVC), FEV1/FVC], serum inflammatory cytokines [tumor necrosis factor-α (TNF-α), C-reactive protein level (CRP) ]levels, the occurrence of adverse reactions were compared. Results There were no statistically significant differences in the levels of FEV1, FVC, and FEV1/FVC before treatment (P＞0.05). After 5 days of treatment, the levels of FEV1, FVC,and FEV1/FVC in the three groups were higher than those before treatment, and the difference were statistically significant (P＜0.05). The FEV1, FVC, FEV1/FVC levels in group B were higher than those in group C, the differences were statistically significant (P＜0.05). Ther was statistically significant difference in the above indicators of three groups (P＜0.05). The levels of serum TNF-α and CRP in the three groups before and after treatment were not statistically significant (P＞0.05); after 5 days of treatment, the levels of serum TNF-α and CRP in the three groups were lower than those before treatment (P ＜0.05). After 5 days of treatment, the total incidence of adverse reactions in groups A and B(40.00%, 35.00%) were higher than that in group C (5.00%), the differences were statistically significant (P＜0.05); adverse reactions in three groups, the difference in total incidence was statistically significant (P＜0.05). Conclusion Both intravenous drip therapy with Methylprednisolone and atomized inhalation therapy with Budesonide can effectively improve the lung function of AECOPD patients, reduce patients′ serum inflammatory factor levels, however, but the safety of Budesonide atomization inhalation therapy is higher.
|
|
|
|
|
|
| [1] |
时桂英，耿红彬.糖皮质激素不同给药途径对慢性阻塞性肺疾病急性加重期患者的临床疗效比较[J].医药导报，2018，37（S1）：27-29.
|
| [2] |
Moretti M，Fagnani S.Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD[J].Int J Chron Obstruct Pulmon Dis，2018，15（2）：235-235.
|
| [3] |
王艳飞，薛燕，王红燕，等.雾化吸入与全身应用糖皮质激素在AECOPD 中的临床研究[J].实用心脑肺血管病杂志，2011，19（3）：361-362.
|
| [4] |
Taniguchi A，Miyahara N，Oda N，et al.Protective effects of bisoprolol against acute exacerbation in moderate-to-severe chronic obstructive pulmonary disease[J].Acta Med Okayama，2017，71（5）：453-457.
|
| [5] |
王辉，张红超，张江丽.雾化吸入糖皮质激素治疗AECOPD 的临床观察[J].现代生物医学进展，2011，11（4）：735-737.
|
| [6] |
Stefan MS，Pekow PS，Shieh MS，et al.Hospital volume and outcomes of noninvasive ventilation in patients Hospitalized with an acute exacerbation of chronic obstructive pulmonary disease[J].Crit Care Med，2016，45（1）：20-27.
|
| [7] |
刘本洪，周宁，孙明祥，等.糖皮质激素吸入治疗对COPD急性加重期患者血清和痰液中细胞因子的影响[J].实用临床医药杂志，2016，20（11）：32-34.
|
| [9] |
吴刚.糖皮质激素不同给药方式对AECOPD 患者炎症因子及肺功能的影响[J].临床肺科杂志，2016，21（11）：2018-2020.
|
| [11] |
王美玲，秦晓鸥，王春荣，等.沙美特罗替卡松对慢性阻塞性肺疾病急性加重期患者炎症因子和肺功能的影响[J].国际呼吸杂志，2019，39（12）：911-915.
|
| [12] |
李成博，刘璐，海鑫.糖皮质激素联合复方异丙托溴胺治疗慢性阻塞性肺疾病急性加重期的效果及对血清炎性因子水平的影响[J].四川医学，2018，39（3）：316-319.
|
| [8] |
Morantes-Caballero JA，Fajardo Rodriguez HA.Effects of air pollution on acute exacerbation of chronic obstructive pulmonary disease: a descriptive retrospective study （pol-AECOPD)[J].Int J Chron Obstruct Pulmon Dis，2019，14（2）：1549.
|
| [10] |
Myers LC，Faridi MK，Currier P，et al.ICU utilization for patients with Acute exacerbation of chronic obstructive pulmonary disease receiving noninvasive ventilation[J].Crit Care Med，2019，47（5）：677-684.
|
| [13] |
钟佰强，钱丽芬，黄宝贤，等.不同剂量糖皮质激素对慢性阻塞性肺疾病患者急性加重期炎性介质的影响及临床意义[J].中华老年医学杂志，2014，33（4）：376-379.
|
| [14] |
吴胜，饶平，吴清松.两种糖皮质激素给药方案治疗老年AECOPD 患者的临床观察[J].中国药房，2017，28（14）：1972-1975.
|
| [15] |
雷思，陈平.糖皮质激素在AECOPD 中的应用研究进展[J].国际呼吸杂志，2016，37（2）：150-152.
|
| [16] |
徐文娟，魏雅茹，徐双明.糖皮质激素治疗嗜酸粒细胞阳性慢性阻塞性肺疾病急性加重期患者的临床疗效观察[J].实用心脑肺血管病杂志，2016，9（2）：1-3.
|
| [17] |
陈宇洁，董桂英，杨凌麟.大剂量雾化吸入糖皮质激素对慢性阻塞性肺疾病患者的影响[J].华西医学，2008，22（5）：179-180.
|
| [18] |
苗深文，孙丽.雾化吸入与静脉用糖皮质激素在治疗AECOPD 的疗效观察[J].临床肺科杂志，2011，16（3）：444-445.
|
|
|
|
